Current status and future role of brain PET/MRI in clinical and research settings

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 42, Issue 3, 2015, Pages 512-526

  Werner, P ^a   Barthel, H ^a   Drzezga, A ^b   Sabri, O ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Brain tumours; Dementia; Functional MRI; Molecular imaging; PET MRI; Stroke

Indexed keywords

AMYLOID BETA PROTEIN; FLUORODEOXYGLUCOSE F 18;

BASIC RESEARCH; BRAIN FUNCTION; BRAIN TUMOR; CEREBROVASCULAR ACCIDENT; DEMENTIA; DIAGNOSTIC VALUE; EPILEPSY; HUMAN; IMAGE ANALYSIS; INFORMATION PROCESSING; NEURORADIOLOGIST; NEUROVASCULAR DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMEDICAL PERSONNEL; POSITRON EMISSION TOMOGRAPHY; REVIEW; TASK PERFORMANCE; VASCULAR DISEASE; WORKFLOW; ANIMAL; BRAIN; BRAIN DISEASES; BRAIN MAPPING; COMPUTER ASSISTED DIAGNOSIS; PHYSIOLOGY; PROCEDURES; SCINTISCANNING; TRENDS;

ANIMALS; BRAIN; BRAIN DISEASES; BRAIN MAPPING; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 84925541260     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2970-9     Document Type: Review

References (104)

1. Dukart J, Mueller K, Horstmann A, Barthel H, Möller HE, Villringer A, et al. Combined evaluation of FDG-PET and MRI improves detection and differentiation of dementia. PLoS One. 2011;6:e18111.
2. Jack Jr CR, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain J Neurol. 2008;131:665–80.
3. Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Müller H-W, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain J Neurol. 2005;128:678–87.
4. Pirotte BJ, Levivier M, Goldman S, Massager N, Wikler D, Dewitte O, et al. Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery. 2009;64:471–81; discussion 481.
5. Dunet V, Maeder P, Nicod-Lalonde M, Lhermitte B, Pollo C, Bloch J, et al. Combination of MRI and dynamic FET PET for initial glioma grading. Nuklearmedizin. 53:155–61.
6. Catana C, Drzezga A, Heiss W-D, Rosen BR. PET/MRI for neurologic applications. J Nucl Med. 2012;53:1916–25.
7. Heiss W-D. Radionuclide imaging in ischemic stroke. J Nucl Med. 2014;55:1831–41.
8. Zhang K, Herzog H, Mauler J, Filss C, Okell TW, Kops ER, et al. Comparison of cerebral blood flow acquired by simultaneous [15O]water positron emission tomography and arterial spin labeling magnetic resonance imaging. J Cereb Blood Flow Metab. 2014;34:1373–80.
9. Rischpler C, Nekolla SG, Dregely I, Schwaiger M. Hybrid PET/MR imaging of the heart: potential, initial experiences, and future prospects. J Nucl Med. 2013;54:402–15.
10. Bolus NE, George R, Washington J, Newcomer BR. PET/MRI: the blended-modality choice of the future? J Nucl Med Technol. 2009;37:63–71. quiz 72–73.
11. Beyer T, Antoch G, Müller S, Egelhof T, Freudenberg LS, Debatin J, et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med. 2004;45 Suppl 1:25S–35.
12. Gilmore CD, Comeau CR, Alessi AM, Blaine M, El Fakhri GN, Hunt JK, et al. PET/MR imaging consensus paper: a joint paper by the Society of Nuclear Medicine and Molecular Imaging Technologist Section and the Section for Magnetic Resonance Technologists. J Nucl Med Technol. 2013;41:108–13.
13. Carney JP, Townsend DW, Rappoport V, Bendriem B. Method for transforming CT images for attenuation correction in PET/CT imaging. Med Phys. 2006;33:976–83.
14. Navalpakkam BK, Braun H, Kuwert T, Quick HH. Magnetic resonance-based attenuation correction for PET/MR hybrid imaging using continuous valued attenuation maps. Invest Radiol. 2013;48:323–32.
15. Berker Y, Franke J, Salomon A, Palmowski M, Donker HC, Temur Y, et al. MRI-based attenuation correction for hybrid PET/MRI systems: a 4-class tissue segmentation technique using a combined ultrashort-echo-time/Dixon MRI sequence. J Nucl Med. 2012;53:796–804.
16. Andersen FL, Ladefoged CN, Beyer T, Keller SH, Hansen AE, Højgaard L, et al. Combined PET/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone. Neuroimage. 2014;84:206–16.
17. Keereman V, Fierens Y, Broux T, De Deene Y, Lonneux M, Vandenberghe S. MRI-based attenuation correction for PET/MRI using ultrashort echo time sequences. J Nucl Med. 2010;51:812–8.
18. Poynton CB, Chen KT, Chonde DB, Izquierdo-Garcia D, Gollub RL, Gerstner ER, et al. Probabilistic atlas-based segmentation of combined T1-weighted and DUTE MRI for calculation of head attenuation maps in integrated PET/MRI scanners. Am J Nucl Med Mol Imaging. 2014;4:160–71.
19. Rezaei A, Defrise M, Nuyts J. ML-reconstruction for TOF-PET with simultaneous estimation of the attenuation factors. IEEE Trans Med Imaging. 2014;33:1563–72.
20. Delso G, Fürst S, Jakoby B, Ladebeck R, Ganter C, Nekolla SG, et al. Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med. 2011;52:1914–22.
21. Oakes TR, Johnstone T, Ores Walsh KS, Greischar LL, Alexander AL, Fox AS, et al. Comparison of fMRI motion correction software tools. Neuroimage. 2005;28:529–43.
22. Catana C, Benner T, van der Kouwe A, Byars L, Hamm M, Chonde DB, et al. MRI-assisted PET motion correction for neurologic studies in an integrated MR-PET scanner. J Nucl Med. 2011;52:154–61.
23. Fung EK, Carson RE. Cerebral blood flow with [15O]water PET studies using an image-derived input function and MR-defined carotid centerlines. Phys Med Biol. 2013;58:1903–23.
24. Su Y, Arbelaez AM, Benzinger TLS, Snyder AZ, Vlassenko AG, Mintun MA, et al. Noninvasive estimation of the arterial input function in positron emission tomography imaging of cerebral blood flow. J Cereb Blood Flow Metab. 2013;33:115–21.
25. Olivot J-M, Mlynash M, Thijs VN, Kemp S, Lansberg MG, Wechsler L, et al. Optimal Tmax threshold for predicting penumbral tissue in acute stroke. Stroke J Cereb Circ. 2009;40:469–75.
26. Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology. 1999;213:521–5.
27. Chan T. Computerized method for automatic evaluation of lean body mass from PET/CT: comparison with predictive equations. J Nucl Med. 2012;53:130–7.
28. Acosta-Cabronero J, Williams GB, Cardenas-Blanco A, Arnold RJ, Lupson V, Nestor PJ. In vivo quantitative susceptibility mapping (QSM) in Alzheimer’s disease. PLoS One. 2013;8:e81093.
29. Rivlin M, Horev J, Tsarfaty I, Navon G. Molecular imaging of tumors and metastases using chemical exchange saturation transfer (CEST) MRI. Sci Rep. 2013;3:3045.
30. Sorbi S, Hort J, Erkinjuntti T, Fladby T, Gainotti G, Gurvit H, et al. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012;19:1159–79.
31. Frisoni GB, Fox NC, Jack Jr CR, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6:67–77.
32. Frisoni GB, Bocchetta M, Chételat G, Rabinovici GD, de Leon MJ, Kaye J, et al. Imaging markers for Alzheimer disease: which vs how. Neurology. 2013;81:487–500.
33. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9:119–28.
34. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486–510.
35. Heiss WD, Kessler J, Szelies B, Grond M, Fink G, Herholz K. Positron emission tomography in the differential diagnosis of organic dementias. J Neural Transm Suppl. 1991;33:13–9.
36. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med. 2008;49:390–8.
37. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275–83.
38. Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2013;40:104–14.
39. Barthel H, Gertz H-J, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424–35.
40. Hsiao I-T, Huang C-C, Hsieh C-J, Hsu W-C, Wey S-P, Yen T-C, et al. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging. 2012;39:613–20.
41. Jones DT, Machulda MM, Vemuri P, McDade EM, Zeng G, Senjem ML, et al. Age-related changes in the default mode network are more advanced in Alzheimer disease. Neurology. 2011;77:1524–31.
42. Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry. 2010;67:584–7.
43. Myers N, Pasquini L, Göttler J, Grimmer T, Koch K, Ortner M, et al. Within-patient correspondence of amyloid-β and intrinsic network connectivity in Alzheimer’s disease. Brain J Neurol. 2014;137:2052–64.
44. Griffa A, Baumann PS, Thiran J-P, Hagmann P. Structural connectomics in brain diseases. Neuroimage. 2013;80:515–26.
45. Alsop DC, Dai W, Grossman M, Detre JA. Arterial spin labeling blood flow MRI: its role in the early characterization of Alzheimer’s disease. J Alzheimers Dis. 2010;20:871–80.
46. Kendziorra K, Wolf H, Meyer PM, Barthel H, Hesse S, Becker GA, et al. Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer’s disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging. 2011;38:515–25.
47. Meyer PM, Strecker K, Kendziorra K, Becker G, Hesse S, Woelpl D, et al. Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry. 2009;66:866–77.
48. Jagust W. Time for tau. Brain. 2014;137:1570–1.
49. Bailey DL, Barthel H, Beuthin-Baumann B, Beyer T, Bisdas S, Boellaard R, et al. Combined PET/MR: Where are we now? Summary report of the second international workshop on PET/MR imaging April 8-12, 2013, Tubingen, Germany. Mol Imaging Biol. 2014;16:295–310
50. Garibotto V, Heinzer S, Vulliemoz S, Guignard R, Wissmeyer M, Seeck M, et al. Clinical applications of hybrid PET/MRI in neuroimaging. Clin Nucl Med. 2013;38:e13–8.
51. Drzezga A, Barthel H, Minoshima S, Sabri O. Potential clinical applications of PET/MR imaging in neurodegenerative diseases. J Nucl Med. 2014;55 Suppl 2;47S–57S.
52. Schmidt H, Schwenzer NF, Bezrukov I, Mantlik F, Kolb A, Kupferschläger J, et al. On the quantification accuracy, homogeneity, and stability of simultaneous positron emission tomography/magnetic resonance imaging systems. Invest Radiol. 2014;49:373–81.
53. Hitz S, Habekost C, Fürst S, Delso G, Förster S, Ziegler S, et al. Systematic comparison of the performance of integrated whole-body PET/MR imaging to conventional PET/CT for 18F-FDG brain imaging in patients examined for suspected dementia. J Nucl Med. 2014;55:923–31.
54. Barker 2nd FG, Chang SM, Huhn SL, Davis RL, Gutin PH, McDermott MW, et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer. 1997;80:936–41.
55. Scott JN, Brasher PMA, Sevick RJ, Rewcastle NB, Forsyth PA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology. 2002;59:947–9.
56. Kruser TJ, Mehta MP, Robins HI. Pseudoprogression after glioma therapy: a comprehensive review. Expert Rev Neurother. 2013;13:389–403.
57. Duffau H. A new philosophy in surgery for diffuse low-grade glioma (DLGG): oncological and functional outcomes. Neurochirurgie. 2013;59:2–8.
58. Galldiks N, Kracht LW, Dunkl V, Ullrich RT, Vollmar S, Jacobs AH, et al. Imaging of non- or very subtle contrast-enhancing malignant gliomas with [11C]-methionine positron emission tomography. Mol Imaging. 2011;10:453–9.
59. Galldiks N, Ullrich R, Schroeter M, Fink GR, Jacobs AH, Kracht LW. Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging. 2010;37:84–92.
60. Bangiyev L, Rossi Espagnet MC, Young R, Shepherd T, Knopp E, Friedman K, et al. Adult brain tumor imaging: state of the art. Semin Roentgenol. 2014;49:39–52.
61. Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003;24:1989–98.
62. Law M, Yang S, Babb JS, Knopp EA, Golfinos JG, Zagzag D, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol. 2004;25:746–55.
63. La Fougère C, Suchorska B, Bartenstein P, Kreth F-W, Tonn J-C. Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol. 2011;13:806–19.
64. Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol. 2006;27:1432–7.
65. Ullrich RT, Kracht L, Brunn A, Herholz K, Frommolt P, Miletic H, et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med. 2009;50:1962–8.
66. Singhal T, Narayanan TK, Jacobs MP, Bal C, Mantil JC. 11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. J Nucl Med. 2012;53:1709–15.
67. Pöpperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007;34:1933–42.
68. Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol. 2011;13:307–16.
69. Pirotte B, Goldman S, Massager N, David P, Wikler D, Vandesteene A, et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med. 2004;45:1293–8.
70. Purz S, Mauz-Körholz C, Körholz D, Hasenclever D, Krausse A, Sorge I, et al. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin’s lymphoma. J Clin Oncol. 2011;29:3523–8.
71. Grosu AL, Weber WA, Franz M, Stärk S, Piert M, Thamm R, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:511–9.
72. Pirotte B, Goldman S, Dewitte O, Massager N, Wikler D, Lefranc F, et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg. 2006;104:238–53.
73. Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, et al. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med. 2010;51:1198–205.
74. Bisdas S, Ritz R, Bender B, Braun C, Pfannenberg C, Reimold M, et al. Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes. Invest Radiol. 2013;48:295–301.
75. Preuss M, Werner P, Barthel H, Nestler U, Christiansen H, Hirsch FW, et al. Integrated PET/MRI for planning navigated biopsies in pediatric brain tumors. Childs Nerv Syst. 30:1399–403.
76. Werner P, Fritzsch D, Holland H, Bauer M, Krupp W, Hoffmann K-T, et al. Definition of primary and secondary glioblastoma – letter. Clin Cancer Res. 2014;20:2011–2.
77. Sharma H. Multiparametric imaging and MR image texture analysis in brain tumors (PhD thesis). The University of Western Ontario; 2014.
78. Artan Y, Yetik IS, Haider MA. Automated prostate cancer localization with multiparametric magnetic resonance imaging. In: El-Baz AS, Saba L, Suri JS, editors. Abdomen and thoracic imaging: an engineering and clinical perspective. New York: Springer; 2014. p. 559–86.
79. Prior FW, Fouke SJ, Benzinger T, Boyd A, Chicoine M, Cholleti S, et al. Predicting a multi-parametric probability map of active tumor extent using random forests. Conf Proc IEEE Eng Med Biol Soc. 2013;2013:6478–81.
80. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–29.
81. Heiss WD, Grond M, Thiel A, von Stockhausen HM, Rudolf J, Ghaemi M, et al. Tissue at risk of infarction rescued by early reperfusion: a positron emission tomography study in systemic recombinant tissue plasminogen activator thrombolysis of acute stroke. J Cereb Blood Flow Metab. 1998;18:1298–307.
82. Thijs VN, Adami A, Neumann-Haefelin T, Moseley ME, Marks MP, Albers GW. Relationship between severity of MR perfusion deficit and DWI lesion evolution. Neurology. 2001;57:1205–11.
83. Merino JG, Warach S. Imaging of acute stroke. Nat Rev Neurol. 2010;6:560–71.
84. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. 2006;60:508–17.
85. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009;8:141–50.
86. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7:299–309.
87. Bokkers RP, Bremmer JP, van Berckel BNM, Lammertsma AA, Hendrikse J, Pluim JPW, et al. Arterial spin labeling perfusion MRI at multiple delay times: a correlative study with H(2)(15)O positron emission tomography in patients with symptomatic carotid artery occlusion. J Cereb Blood Flow Metab. 2010;30:222–9.
88. Nael K, Meshksar A, Liebeskind DS, Coull BM, Krupinski EA, Villablanca JP. Quantitative analysis of hypoperfusion in acute stroke: arterial spin labeling versus dynamic susceptibility contrast. Stroke J Cereb Circ. 2013;44:3090–6.
89. Zaro-Weber O, Moeller-Hartmann W, Heiss W-D, Sobesky J. Maps of time to maximum and time to peak for mismatch definition in clinical stroke studies validated with positron emission tomography. Stroke J Cereb Circ. 2010;41:2817–21.
90. O’Brien TJ, Hicks RJ, Ware R, Binns DS, Murphy M, Cook MJ. The utility of a 3-dimensional, large-field-of-view, sodium iodide crystal–based PET scanner in the presurgical evaluation of partial epilepsy. J Nucl Med. 2001;42:1158–65.
91. Lee KK, Salamon N. [18F]fluorodeoxyglucose-positron-emission tomography and MR imaging coregistration for presurgical evaluation of medically refractory epilepsy. AJNR Am J Neuroradiol. 2009;30:1811–6.
92. LoPinto‐Khoury C, Sperling MR, Skidmore C, Nei M, Evans J, Sharan A, et al. Surgical outcome in PET‐positive, MRI‐negative patients with temporal lobe epilepsy. Epilepsia. 2012;53:342–8.
93. Chassoux F, Rodrigo S, Semah F, Beuvon F, Landre E, Devaux B, et al. FDG-PET improves surgical outcome in negative MRI Taylor-type focal cortical dysplasias. Neurology. 2010;75:2168–75.
94. Gok B, Jallo G, Hayeri R, Wahl R, Aygun N. The evaluation of FDG-PET imaging for epileptogenic focus localization in patients with MRI positive and MRI negative temporal lobe epilepsy. Neuroradiology. 2013;55:541–50.
95. Purz S, Sabri O, Viehweger A, Barthel H, Kluge R, Sorge I, et al. Potential pediatric applications of PET/MR. J Nucl Med. 2014;55 Suppl 2:32S–39S.
96. Sander CY, Hooker JM, Catana C, Normandin MD, Alpert NM, Knudsen GM, et al. Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI. Proc Natl Acad Sci U S A. 2013;110:11169–74.
97. Wehrl HF, Martirosian P, Schick F, Reischl G, Pichler BJ. Assessment of rodent brain activity using combined [(15)O]H2O-PET and BOLD-fMRI. Neuroimage. 2014;89:271–9.
98. Wehrl HF, Hossain M, Lankes K, Liu C-C, Bezrukov I, Martirosian P, et al. Simultaneous PET-MRI reveals brain function in activated and resting state on metabolic, hemodynamic and multiple temporal scales. Nat Med. 2013;19:1184–9.
99. Riedl V, Bienkowska K, Strobel C, Tahmasian M, Grimmer T, Förster S, et al. Local activity determines functional connectivity in the resting human brain: a simultaneous FDG-PET/fMRI study. J Neurosci. 2014;34:6260–6.
100. Schultz CC, Fusar-Poli P, Wagner G, Koch K, Schachtzabel C, Gruber O, et al. Multimodal functional and structural imaging investigations in psychosis research. Eur Arch Psychiatry Clin Neurosci. 2012;262 Suppl 2:S97–106.
101. Uppal R, Catana C, Ay I, Benner T, Sorensen AG, Caravan P. Bimodal thrombus imaging: simultaneous PET/MR imaging with a fibrin-targeted dual PET/MR probe – feasibility study in rat model. Radiology. 2011;258:812–20.
102. Morbelli S, Perneczky R, Drzezga A, Frisoni GB, Caroli A, van Berckel BN, et al. Metabolic networks underlying cognitive reserve in prodromal Alzheimer disease: a European Alzheimer disease consortium project. J Nucl Med. 2013;54:894–902.
103. Yakushev I, Chételat G, Fischer FU, Landeau B, Bastin C, Scheurich A, et al. Metabolic and structural connectivity within the default mode network relates to working memory performance in young healthy adults. Neuroimage. 2013;79:184–90.
104. Villien M, Wey H-Y, Mandeville JB, Catana C, Polimeni JR, Sander CY, et al. Dynamic functional imaging of brain glucose utilization using fPET-FDG. Neuroimage. 2014;100:192–9.